Routine

Maturity-onset diabetes of the young (MODY)

MODY · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Monogenic autosomal dominant diabetes presenting in young, often non-obese people with a strong family history and preserved beta-cell function. Correct diagnosis changes treatment dramatically, often allowing sulfonylureas or no treatment.

Red flags

  • Ketosis or rapid deterioration (reconsider type 1 diabetes)
  • Pregnancy with GCK-MODY (fetal genotype guides maternal treatment)
  • Severe hyperglycaemia unresponsive to sulfonylurea

Assessment

Differential diagnosis

  • Type 1 diabetes
  • Type 2 diabetes
  • Neonatal diabetes
  • Latent autoimmune diabetes of adults
  • Secondary diabetes

Investigations

  • GAD and islet autoantibodies (negative in MODY)
  • C-peptide (detectable/preserved outside honeymoon)
  • Genetic testing (HNF1A, HNF4A, GCK and others)
  • Fasting glucose and HbA1c
  • MODY probability calculator to guide testing

Management

  • Suspect MODY in antibody-negative, C-peptide-positive young diabetics with a multigenerational family history
  • Use clinical features and the MODY probability model to select candidates
  • Send targeted genetic panel for common subtypes
  • GCK-MODY: stop treatment (mild stable fasting hyperglycaemia, no complications) except in pregnancy
  • HNF1A/HNF4A-MODY: use low-dose sulfonylurea as first-line, highly effective therapy
  • Transition patients mislabelled as type 1 off insulin where appropriate and safe
  • Screen first-degree relatives and offer predictive testing
  • Counsel on 50% inheritance risk and implications for pregnancy
  • Arrange complication surveillance for subtypes with microvascular risk

Drugs & doses

Gliclazide 20-40 mg PO once daily (low dose, HNF1A/HNF4A)
No pharmacotherapy for most GCK-MODY
Insulin only if sulfonylurea inadequate or in pregnancy as needed

Disposition

Refer to a specialist/genetics-linked diabetes service for confirmatory testing, family cascade screening and treatment reassignment.

Complications & pitfalls

  • Inappropriate lifelong insulin if misdiagnosed as type 1
  • Microvascular complications in HNF1A/HNF4A if poorly controlled
  • Macrosomia/fetal growth effects in GCK pregnancies
  • Hypoglycaemia if sulfonylurea overdosed

Exam pearls

  • Antibody-negative, C-peptide-positive diabetes diagnosed before 35 with strong family history should prompt MODY testing
  • GCK-MODY needs no treatment and carries no excess complication risk outside pregnancy
  • HNF1A-MODY patients are exquisitely sensitive to low-dose sulfonylureas
  • A correct genetic diagnosis can free a patient from insulin for life

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.